Case Reports
23 April 2024
Vol. 18 No. 2 (2024)
A rare case of thrombocytopenia secondary to taking febuxostat
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
961
Views
475
Downloads
296
HTML
Authors
A new and powerful selective xanthine oxidase inhibitor called febuxostat seems to be well tolerated by all patient populations, even those who are allopurinol-sensitive. Thrombocytopenia is an extremely uncommon side effect. The case of a 63- year-old man who presented with sudden thrombocytopenia and was ultimately linked to febuxostat consumption is described below. The case happened in our department.
Altmetrics
Downloads
Download data is not yet available.
Citations
Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag 2008;4:1209-20. DOI: https://doi.org/10.2147/TCRM.S3310
Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003;278:1848-55. DOI: https://doi.org/10.1074/jbc.M208307200
Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/ xanthine dehydrogenase. Life Sci 2005;76:1835-47. DOI: https://doi.org/10.1016/j.lfs.2004.10.031
Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. J Nippon Med Sch 2008;75:2-3. DOI: https://doi.org/10.1272/jnms.75.2
Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 1993;241:183-8. DOI: https://doi.org/10.1016/0014-2999(93)90201-R
Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187-94. DOI: https://doi.org/10.1345/aph.1H121
Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new nonpurine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005;12:22-34. DOI: https://doi.org/10.1097/00045391-200501000-00005
How to Cite
A rare case of thrombocytopenia secondary to taking febuxostat. (2024). Italian Journal of Medicine, 18(2). https://doi.org/10.4081/itjm.2024.1724
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Federico Pasin, Emanuela Porro, Francesco Frattini, Pierpaolo Vescovi, Massimo Franchini, Paolo Sansoni, Thrombocytopenia induced by a taurine-containing energy drink: an adverse reaction to herbal medicine , Italian Journal of Medicine: Vol. 8 No. 4 (2014)
- Giovanni Gulli, Luigi de Filippis, Febuxostat: a new drug for an old disease. Do we really need it? , Italian Journal of Medicine: Vol. 3 No. 2 (2009)
- Manuel Monti, Lucia Stefanecchia, Manolo Filippucci, Alessio Monti, Giovanni Maria Vincentelli, Francesco Borgognoni, A strange case of Evans syndrome , Italian Journal of Medicine: Vol. 7 No. 4 (2013)
- Volkan Karakuş, Egemen Kaya, Yelda Dere, Fahri Åžahin, Different clinical courses with the same findings: two cases of paroxysmal nocturnal hemoglobinuria presenting with thrombocytopenia , Italian Journal of Medicine: Vol. 15 No. 3 (2021)
- Alberto Mazza, Salvatore Lenti, Maria D'Avino, Giuliano Pinna, Giancarlo Antonucci, Sara Ciarla, Fabrizio Colombo, Raffaele Costa, Susanna Cozzio, Alessandro De Palma, Erica Del Signore, Massimo Errico, Fabio Fiammengo, Giuseppe Iosa, Massimiliano Loreno, Federica Lorenzi, Rocco Paternò, Martino Pengo, Cecilia Politi, Marcello Rattazzi, Maurizio Renis, Flavio Tangianu, Nicola Tarquinio, Mario Trottini, Gianluigi Scannapieco, Giorgio Vescovo, Gualberto Gussoni, Mauro Campanini, Dario Manfellotto, Andrea Fontanella, Self-reported hypertension, dyslipidemia and hyperuricemia management by Italian Internal Medicine Units: a national survey of the FADOI Study Group in Cardiovascular Medicine , Italian Journal of Medicine: Vol. 11 No. 4 (2017)
- Zafer Gashi, Muhamet Kadrija, Pathological changes of biochemical, hematological and coagulation analyses in patients with COVID-19 disease , Italian Journal of Medicine: Vol. 18 No. 2 (2024)
- Deborah Melis, Gianluca Michelis, Marcello Brignone, Marina Cavaliere, Rodolfo Tassara, Thrombotic thrombocytopenic purpura (TTP) or Moschowitz syndrome: a true hematologic emergency , Italian Journal of Medicine: Vol. 5 No. 4 (2011)
- G. Airoldi, M. Campanini, Fondaparinux , Italian Journal of Medicine: Vol. 2 No. 1 (2008)
- P35 | Adverse reaction to rituximab: an unusual case of drug- induced trombocytopenia , Italian Journal of Medicine: Vol. 19 No. 1(s1) (2025): XXX FADOI Italian Congress | 10-12 May 2025
- Paolo Agostinis, Cathryn Anne Scott, Weber-Christian disease: ultrasound can see it , Italian Journal of Medicine: Vol. 8 No. 1 (2014)
1-10 of 63
Next
You may also start an advanced similarity search for this article.